BACKGROUND: Despite the approval of azacitidine in 2004 and the approval of decitabine in 2006 in the United States for chronic myelomonocytic leukemia (CMML), the overall survival (OS) benefit with hypomethylating agent (HMA) therapy is unclear. METHODS: Older adults (age 66 years) who had been diagnosed with CMML from 2001 to 2011 were selected from the Surveillance, Epidemiology, and End Results-Medicare database, and propensity score matching was used to match patients who had been diagnosed after HMA approval (2007)(2008)(2009)(2010)(2011) and had received HMA treatment with patients diagnosed before HMA approval (2001)(2002)(2003). Cox proportional hazards models with the matched sample were used to assess the change in OS. A second matched cohort of patients who did not receive HMA after approval and patients diagnosed before HMA approval was used to evaluate survival change attributable to other potential differences between the 2 time periods, such as improved supportive care. RESULTS: Among 1378 older adults diagnosed with CMML, the median OS was 13 months, and 18.8% received HMAs. In the primary matched analysis, with 225 HMA users diagnosed in 2007-2011 and 395 patients diagnosed in 2001-2003, the median OS times were 17 and 11 months, respectively (hazard ratio, 0.72; 95% confidence interval [CI], 0.58-0.91; P 5.005). In a secondary analysis, the risk of death did not differ between 395 propensity score-matched HMA nonusers diagnosed in 2007-2011 and 484 patients diagnosed in 2001-2003 (hazard ratio, 1.09; 95% CI, 0.91-1.32; P 5.34). CONCLUSIONS: Despite limited evidence, HMAs are commonly used to treat older CMML patients. The use of HMAs was associated with a 28% reduction in the risk of death in adjusted analyses. Improvements in supportive care do not appear to account for temporal improvements in OS.
INTRODUCTION
Chronic myelomonocytic leukemia (CMML) is a rare hematological malignancy with an estimated age-adjusted annual incidence in the United States of 0.3 to 0.4 per 100,000 persons. 1 CMML was long classified as a subtype of myelodysplastic syndrome (MDS) before it was placed in a new separate category (MDS/myeloproliferative neoplasm overlap) in the World Health Organization's 2008 classification. 2 Epidemiological, biological, and therapeutic evaluations of patients with CMML were historically conducted within MDS studies and not as a separate group. Therefore, most of our knowledge about therapeutic interventions is derived from large randomized MDS trials that included small subsets of CMML patients or small, single-center trials.
Older adults with CMML classified as lower risk by various risk stratification tools are generally treated with observation or supportive measures. The management of higher risk patients may include the use of the hypomethylating agents (HMAs) azacitidine and decitabine with the goal of extending survival. Very few patients undergo allogeneic hematopoietic stem cell transplantation (allo-SCT), the only potentially curative approach.
The use of HMAs in large randomized trials for patients with higher risk MDS led to hematological responses, quality-of-life improvements, and survival improvements (azacitidine only), and this resulted in the Food and Drug Administration's approval of azacitidine in 2004 and decitabine in 2006 in the United States. [4] [5] [6] [7] Both drugs were also approved for use in CMML because the disease was still classified as a subtype of MDS. However, a survival advantage with HMA therapy has not been demonstrated specifically for CMML.
The Surveillance, Epidemiology, and End Results (SEER)-Medicare database is particularly well suited for studying patterns of care, outcomes, and the effectiveness of therapies for rare malignancies for whom the majority of patients are 65 years old or older at the time of diagnosis, including CMML (median age at diagnosis, 76 years; patients aged 65 years at diagnosis, 84%). [8] [9] [10] In a prior SEER-Medicare analysis of patients diagnosed with CMML in 2001-2005, we demonstrated that patients diagnosed with CMML had a significantly shorter median overall survival (OS; 13.3 vs 23.3 months; P < .0001) and a lower 3-year survival rate (19% vs 36%; P < .0001) than patients with MDS. 11 However, the majority of the patients in that analysis had been diagnosed before the first approval of an HMA, and only 5.8% of the 792 patients in that cohort received an HMA. 11 In the current study, we evaluate patterns of HMA use in CMML patients in the United States over a longer time span with significant coverage of the post-HMA approval period (patients diagnosed in 2001-2011), and we study the impact of HMA use on survival with a large populationbased database.
Because observational studies are subject to a selection bias on account of unobserved factors, we sought to take advantage of the market entry of HMAs in the United States in 2004-2006 as a natural experiment for studying the effect of HMAs on survival. In this study, our primary analysis compares older adults diagnosed with CMML and treated with HMAs after 2006 and those diagnosed before 2004 (the year of first HMA approval), who had characteristics similar to those of patients in the post-2006 period. An alternative hypothesis is that general improvements in supportive care improved survival over time. To test this alternative, we compare the survival of older adults diagnosed after 2006 who did not receive HMAs with the survival of those diagnosed in the pre-HMA approval period.
MATERIALS AND METHODS

Data Source and Study Sample
In this retrospective cohort study, we used the SEERMedicare linked database. The SEER database captures 15 The date of diagnosis was assigned to the first day of the month of diagnosis provided by SEER. The inclusion criteria included being 66 years old or older at diagnosis, being continuously enrolled in Medicare Parts A and B, and not being enrolled in Medicare Advantage from 12 months before the CMML diagnosis until death or the end of followup. Patients were excluded if their diagnosis was reported by death certificate or autopsy only, they had a missing diagnosis date, or they had received an HMA before their CMML diagnosis (Fig. 1) . Prior to analysis, the Yale Human Investigation Committee determined that this study did not directly involve human subjects. Therefore, review and approval by the Human Investigation Committee was not necessary.
Variables of Interest
Our key variable of interest was the receipt of any HMA. We identified therapies, including HMAs, erythropoietin-stimulating agents, and allo-SCT using the Healthcare Common Procedural Coding System codes on claims (Supporting Table 1 [see online supporting information]). HMA receipt was identified as any claim for azacitidine or decitabine administration after the CMML diagnosis. We also counted the number of HMA cycles, with a cycle defined as at least 3 distinct days of HMA use separated by a gap of 2 weeks or more. Erythropoietin-stimulating agent use was assessed from 12 months before the CMML diagnosis through the date of the diagnosis. Because classic disease-specific measures of CMML severity such as cytogenetics and blood/bone marrow blast proportions were not available in the data set, we used alternative measures of disease severity, including transfusion needs and hospitalization for bleeding or infections. We used Healthcare Common Procedural Coding System codes to identify transfusions of red blood cells and platelets from 8 weeks before the diagnosis to 4 weeks after the diagnosis. We also looked for hospitalizations with a diagnosis of bleeding or infection from 6 months before the diagnosis through 1 month after the diagnosis month (8 months total).
For patient-level covariates, we used census tractlevel measures (zip code-level measures if not available) linked to SEER-Medicare, including the median household income and the percentage of adults with a high school education or less. In the 12-month period before the diagnosis date, we identified the number of comorbid conditions with the approach developed by Elixhauser et al. 16 We required the relevant diagnosis codes to be present in either a single inpatient claim or 2 or more physician or outpatient claims, with at least 2 that were 30 or more days apart, for the comorbidity to be considered present. The disability status, a validated claim-based proxy for the performance status, was assessed with claims in the year before the diagnosis. 17, 18 Finally, we calculated OS from the date of diagnosis to death or the end of the study, whichever came first.
Statistical Analysis
We used chi-square tests to evaluate categorical variables and the Student's t test to study continuous variables for comparing the distributions of clinical and demographic covariates between different groups of CMML patients.
We classified the sample into 3 analytic subsamples on the basis of the approval dates and HMA treatment ( Because of the assumed survival benefits of HMAs, the inclusion of these 18 patients might have biased our results toward the null, whereas the exclusion of these 18 patients might have caused bias away from the null. Therefore, we decided to adopt the more conservative approach and kept them in the pre-HMA approval group. We conducted a multivariate logistic regression to estimate HMA treatment propensity with the postapproval samples (groups A and B). The covariates in the propensity model included the following: age at diagnosis, sex, race, census tract-level education and income, metro residency, Medicaid dual eligibility, Elixhauser comorbidity index, disability status, hospitalizations for bleeding or infection, and red blood cell and platelet transfusions. The model estimates were used to generate treatment propensity scores for the entire sample (including pre-approval patients). Our primary analysis focused on group A versus the propensity score-matched patients in group C. The secondary analysis compared group B with propensity score-matched patients from group C to evaluate other potential differences between the 2 time periods (2001-2003 vs 2007-2011) such as the effects of supportive care on survival. We used KaplanMeier methods and log-rank testing to compare unadjusted survival between HMA users and HMA nonusers.
We ran Cox proportional hazards models to assess the differences in survival with the propensity score-matched sample. We also report Kaplan-Meier survival estimates and differences from 12 to 60 months for the matched sample, and we used a boot-strapping approach to calculate confidence intervals (CIs), which are not subject to the proportional hazards assumption of a Cox model. Finally, we used Kaplan-Meier methods and log-rank testing to compare unadjusted survival between azacitidine-and decitabine-treated patients. We used SAS 9.4 (SAS Institute, Inc, Cary, North Carolina) to conduct all analyses with 2-sided statistical tests and an a value of .05.
RESULTS
A total of 1378 patients with a CMML diagnosis in the SEER-Medicare database met the eligibility criteria (Fig.  1) . The median age was 79 years (interquartile range [IQR], 73-84 years), 89.7% were white, and 60.6% were male. A total of 1242 patients (90.1%) died during follow-up. The median follow-up from diagnosis was 13 months (IQR, 4-29 months). The median OS of the entire cohort from the date of the CMML diagnosis was 13 months (95% CI, 12-14 months).
During the follow-up period, 259 patients (18.8%) received at least 1 dose of an HMA; they included 119 patients who received only azacitidine (8.6%), 94 who received only decitabine (6.8%), and 46 patients who received both agents (3.3%) at some point during followup (Table 1) . Among CMML patients diagnosed in the pre-HMA approval period (2001) (2002) (2003) , only a small number (18 [3.6%]) subsequently received an HMA. For patients who were diagnosed from 2007 to 2011, the proportion of HMA recipients ranged from 23.5% to 31.0% each year (Fig. 3) . Among those who received an HMA, the median duration from diagnosis to first initiation of the HMA was 2 months (IQR, 1-10 months). Only 14 patients underwent allo-SCT during follow-up (1%). In unadjusted analyses, the OS of patients diagnosed after 2006 was significantly better than the OS of those diagnosed in the pre-approval period ( Fig. 4) .
The median number of HMA cycles received was 5 (IQR, 2-11), with 63% of HMA users receiving 4 or more cycles and 46% receiving 6 or more cycles; this indicated adequate exposure to the drugs, which typically require prolonged exposure to provide a clinical benefit. The median OS of those patients who received 4 or more cycles of HMAs was 22 months (95% CI, 19-25 months).
Propensity Score Matching and Survival
Predictors of HMA receipt for patients diagnosed after 2006 are shown in Supporting Table 3 (see online supporting information). Older patients and patients who were hospitalized for bleeding or infection were less likely to receive HMAs, whereas those who underwent red blood cell or platelet transfusions were more likely to receive HMAs. Standardized differences between the 225 propensity score-matched HMA users who were diagnosed in 2007-2011 (group A) and the 395 propensity score-matched patients who were diagnosed in 2001-2003 (group C) suggested that the distribution of covariates was balanced after matching ( Table 2 ). The median OS times were 17 and 11 months, respectively, and this translated into significantly improved OS with a hazard ratio of 0.72 (95% CI, 0.58-0.91; P 5 .005; Fig. 5A ). The probability of survival was higher among HMA users 
DISCUSSION
The results of our study, based on one of the largest cohorts of older adults with CMML, indicate a significant survival benefit associated with the receipt of an HMA. Specifically, we found that HMA use was associated with a 28% reduction in the risk of death for older CMML patients who were diagnosed after 2006 and received HMAs in comparison with propensity score-matched patients who were diagnosed in 2001-2003. It does not seem that this significant improvement in survival can be explained simply by improvements in supportive care or other potential changes in patient characteristics or treatments over the study period because there was no change in OS between the untreated patients in the post-HMA period and those diagnosed before HMA approval. Importantly, we noticed that the OS difference was significant in the first year after the diagnosis, but the OS benefit associated with HMA use disappeared within 2 years after the diagnosis. This observation of the survival benefit being limited to the first 24 months after the initiation of therapy with HMAs is in line with what has been observed in patients with MDS, who typically experience HMA failure by that time point. 5 Although allo-SCT is considered the only potentially curative therapy, only 1% of older patients with CMML underwent allo-SCT.
Our results confirm that HMAs are commonly used in the United States for the treatment of CMML, and this may be related to the lack of other disease-modifying therapies. 19 Only 1% of older CMML patients in our study underwent allo-SCT, and the vast majority of the patients were treated with palliative approaches. We observed that the OS of older CMML patients as a group has improved since the approval of HMAs (median, 14 vs 10 months; P 5 .013). The factors underlying this improvement could be related to better supportive measures and/or wider use of active therapies. Our results suggest that the use of HMAs is associated with a reduced risk of death in CMML patients diagnosed in 2007-2011 who received Clinical trial data associated with HMA use in CMML are sparse, but our study results are generally consistent with reported outcomes regarding the survival impact of those agents. [4] [5] [6] [7] In each of the 2 large randomized phase 3 trials of azacitidine in MDS, less than 10% of the patients had CMML. 4, 5 Although azacitidine use in the AZA-001 trial was associated with a median OS benefit of 9.5 months in comparison with conventional care (24.5 vs 15 months; hazard ratio, 0.58; P < .0001), such small numbers precluded meaningful OS comparisons for the CMML patients. 5 Similarly, the 2 large randomized phase 3 studies of decitabine in MDS included only a few CMML patients. 6, 7 Neither study showed an improvement in OS in the overall cohorts in comparison with supportive care, and it is not clear whether this is related to biological differences between azacitidine and decitabine or is due to differences in study design. Small retrospective and prospective single-arm studies using decitabine and azacitidine in CMML were also reported, but improvements in OS could not be ascertained. [20] [21] [22] [23] Finally, although we observed no difference in OS between azacitidine-and decitabine-treated patients, it should be noted that this was an unadjusted comparison that did not account for potential differences in patient-or diseaserelated characteristics that might have affected the OS. Small numbers limited the performance of a an adjusted analysis comparing the type of HMA used.
Like any retrospective analysis, our study has limitations. We could not observe some disease-specific characteristics such as blast percentages, blood counts, and cytogenetic/molecular abnormalities in this data set, all of which are factors that likely affect both the survival of patients and the decision by the physician to use HMAs. Nonetheless, we were able to assess the impact of other important prognostic predictors such as age, red blood cell and platelet transfusion needs (which are proxies for severe anemia and thrombocytopenia), and the disability status index 17, 18 and Elixhauser comorbidity index 16 (which are proxies for the performance status and burden of comorbidities, respectively). In addition, our study design takes advantage of a natural experiment, the market entry of HMAs in 2004 and 2006, which tends to limit the bias associated with unobserved confounders. Furthermore, even if the disease-specific characteristics that we could not observe were not randomly distributed in the matched samples, it is conceivable that patients who received HMAs had higher risk disease (ie, higher blast percentages and worse cytogenetics), and this would underestimate, rather than inflate, the impact of HMA use on survival. In summary, to our knowledge, this is the largest reported cohort of patients with CMML treated with HMAs. Despite a lack of randomized clinical trial evidence for their use, these drugs are often used in the United States. In this observational cohort study that used the market entry of HMAs as a natural experiment to assess the impact of HMAs on survival, our findings support the use of HMAs for CMML. In the absence of randomized prospective data, our findings provide the best evidence to date for a survival advantage with the use of HMAs for CMML.
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